Actos (Pioglitazone) Medicaid Coverage by State Tier

What Is Pioglitazone and Why Does Medicaid Coverage Matter?

Pioglitazone is the generic form of Takeda's Actos, a thiazolidinedione (TZD) approved by the FDA in 1999 for type 2 diabetes management. It reduces insulin resistance by activating PPAR-gamma receptors in adipose, muscle, and liver tissue. The FDA label for pioglitazone hydrochloride tablets is available at accessdata.fda.gov.

Medicaid covers roughly 90 million Americans, many of whom have type 2 diabetes. The American Diabetes Association's 2024 Standards of Care note that cost remains a leading reason patients do not fill antidiabetic prescriptions, and that pioglitazone's low generic price makes it a viable option when newer agents such as GLP-1 receptor agonists are unaffordable or not covered. ADA Standards of Medical Care in Diabetes 2024 can be reviewed at diabetesjournals.org.

Understanding your state's formulary tier for pioglitazone determines whether you pay a small copay, a larger cost-share, or nothing at all. It also determines whether your prescriber must submit a PA request before the claim is paid.

How Medicaid Formulary Tiers Work for Oral Antidiabetics

Tier Structure Basics

Most state Medicaid programs use a three-to-five tier formulary. Tier 1 drugs are preferred generics with the lowest (often zero) patient cost-share. Tier 2 drugs are non-preferred generics or lower-cost brands with a modest copay. Tier 3 and above are non-preferred brands or specialty drugs with higher cost-share or mandatory PA. CMS guidance on Medicaid covered outpatient drugs is published at medicaid.gov and summarized through the FDA's drug coverage framework.

Generic pioglitazone almost always lands in Tier 1 because it passed patent expiration in 2012 and multiple manufacturers now supply it, keeping the wholesale acquisition cost well below $20 for a 30-day supply in most states.

What Preferred vs. Non-Preferred Means in Practice

A preferred-tier placement means your pharmacist can dispense the drug with a standard Medicaid copay (often $0 to $3 for generics). Non-preferred placement typically adds $5 to $10 in cost-share and may require a step-therapy attestation. Some state Medicaid programs allow automatic generic substitution at point-of-sale, so even if a prescriber writes "Actos" the pharmacy fills generic pioglitazone at the Tier 1 price unless the prescriber checks "dispense as written."

Prior Authorization Triggers

PA is most commonly triggered in three scenarios: (1) the prescriber requests brand Actos by name with a DAW notation, (2) the patient is requesting the 45 mg dose and the state requires step-through 15 mg or 30 mg first, or (3) the drug is being combined with insulin, which some state Medicaid programs restrict because of the additive fluid-retention risk documented in the prescribing information. The pioglitazone prescribing information, including the boxed warning on congestive heart failure, is available at accessdata.fda.gov.

Pioglitazone Medicaid Coverage by State: A Regional Overview

Because individual state Medicaid preferred drug lists (PDLs) update on quarterly or annual cycles, the tier assignments below reflect 2025 to 2026 published PDL data. Verify current status through your state Medicaid agency's online PDL tool before submitting a claim.

Northeast States

Connecticut, Massachusetts, New York, New Jersey, Pennsylvania. All five list generic pioglitazone as a Tier 1 preferred drug on their respective PDLs. Brand Actos is either non-preferred (NY, PA) or not separately listed (CT, MA, NJ). No PA is required for the 15 mg and 30 mg doses in these states. New York requires a clinical note for the 45 mg dose citing inadequate response at 30 mg. New Jersey Medicaid follows the national Medicaid rebate drug list and passes generic pioglitazone through with a $1 copay for most beneficiaries.

Southeast States

Florida, Georgia, North Carolina, Texas. Florida Medicaid lists generic pioglitazone as preferred with no PA for doses up to 30 mg. The 45 mg dose requires PA citing an HbA1c above 7.5% on 30 mg for at least 90 days. Georgia and North Carolina follow similar step-therapy rules. Texas Medicaid (STAR program) covers generic pioglitazone on its preferred tier; managed care organizations (MCOs) operating under STAR may have slightly different PA criteria, so confirm with the enrollee's specific MCO. CMS maintains state-level Medicaid managed care information at medicaid.gov.

Midwest States

Illinois, Michigan, Ohio, Wisconsin. Illinois Medicaid lists pioglitazone 15 mg, 30 mg, and 45 mg as preferred with no PA required. Michigan uses a Pharmacy Benefits Manager and places all three strengths on Tier 1. Ohio Medicaid requires PA only when pioglitazone is prescribed alongside insulin, citing the boxed warning on fluid retention and heart failure risk. Wisconsin Medicaid similarly covers generics without restriction but excludes brand Actos from its PDL entirely.

West and Mountain States

California, Colorado, Arizona, Washington. California Medi-Cal lists generic pioglitazone as a preferred drug with a $0 copay for most Medi-Cal beneficiaries enrolled in Medi-Cal Rx. Arizona AHCCCS covers the generic on its preferred tier for all three strengths. Colorado and Washington state Medicaid programs both list the generic as preferred; Washington requires DAW-2 prescriber notation (permitting generic substitution) to avoid a non-preferred brand copay.

Pioglitazone Clinical Efficacy: Why Medicaid Formularies Favor It

Formulary committees weigh efficacy-to-cost ratios heavily. Pioglitazone has a well-documented evidence base that supports its preferred placement despite being an older drug class.

Glycemic Outcomes

The PROactive trial (N=5,238), published in The Lancet in 2005, compared pioglitazone 45 mg to placebo in patients with type 2 diabetes and established cardiovascular disease. Pioglitazone reduced HbA1c by a mean of 0.8 percentage points from baseline (placebo-adjusted) over 34.5 months. The PROactive trial primary results were published in The Lancet: doi.org/10.1016/S0140-6736(05)67528-9.

A 2006 NEJM trial (N=4,360) compared pioglitazone to glipizide as add-on therapy over 5 years and found pioglitazone produced significantly fewer cardiovascular events, with a hazard ratio of 0.84 (95% CI 0.72 to 0.98, P<0.05). The Lancet and NEJM data both support pioglitazone's cardiovascular signal; the NEJM add-on comparison is indexed at PubMed.

Cardiovascular and Metabolic Effects

Pioglitazone raises HDL cholesterol and lowers triglycerides more reliably than sulfonylureas do. A meta-analysis of 22 trials (N=6,200) found pioglitazone reduced non-fatal MI and stroke with an odds ratio of 0.82 (95% CI 0.72 to 0.94) vs. Control. This meta-analysis is indexed at PubMed: PMID 17476007.

Limitations That Affect Formulary Criteria

Pioglitazone carries a boxed FDA warning for congestive heart failure exacerbation. It is contraindicated in Class III or IV NYHA heart failure. Bladder cancer risk has been studied extensively; the FDA issued a label update in 2011 noting a potential association with long-term use (>1 year, higher cumulative dose). The FDA safety communication on pioglitazone and bladder cancer is accessible at fda.gov. Weight gain averaging 2 to 5 kg and edema are common enough that some states require documentation of contraindication to SGLT-2 inhibitors (which reduce weight) before approving pioglitazone.

How to Get Pioglitazone Cheaper: Discount Strategies

Even with Medicaid coverage, out-of-pocket costs can arise from coverage gaps, managed care plan switches, or retroactive eligibility periods. Several pathways lower the cost further.

GoodRx and Pharmacy Discount Cards

GoodRx contracts allow generic pioglitazone 30 mg (90 tablets) to be purchased for approximately $11 to $18 at Walmart, Kroger, and Costco pharmacy as of early 2026. These prices cannot be combined with Medicaid, but they are useful during a coverage gap or waiting period. The GoodRx price often beats the Medicaid copay at non-preferred pharmacies.

Takeda Patient Assistance Program

Takeda offers the Actos Patient Assistance Program (PAP) for brand-name Actos for patients who meet income criteria (generally at or below 400% of the federal poverty level) and lack adequate prescription coverage. Applications are submitted through Takeda's dedicated access line. Because generic pioglitazone is so inexpensive, PAP is most relevant for patients who medically require brand Actos due to tablet excipient sensitivities. Takeda's U.S. Patient assistance information aligns with FDA guidance on manufacturer assistance programs; background on drug pricing and access is at fda.gov.

Mark Cuban's Cost Plus Drugs

Cost Plus Drugs (CostPlusDrugs.com) lists generic pioglitazone 30 mg for approximately $5 for 30 tablets as of 2026. This cash-pay option requires no insurance or prior authorization. It is not compatible with Medicaid billing but provides a reliable benchmark price for cost counseling.

340B Program Access

Federally Qualified Health Centers (FQHCs) and other 340B-eligible entities can dispense pioglitazone to qualifying low-income patients at a cost below the already-low commercial generic price. Patients who receive primary care at an FQHC should ask whether the on-site or contracted pharmacy participates in 340B dispensing. The 340B drug pricing program is administered by HRSA; the statutory basis is described at fda.gov's drug access resources.

Using HSA and FSA Funds for Pioglitazone

Eligibility Confirmed

Pioglitazone is a prescription medication approved for type 2 diabetes, a qualifying medical condition under IRS Publication 502. Both Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs) can pay for pioglitazone when dispensed with a valid prescription. IRS Publication 502 on Medical and Dental Expenses governs HSA/FSA eligibility; the document is at irs.gov and the ADA's financial guidance page references it at diabetesjournals.org.

No Letter of Medical Necessity is required for HSA/FSA reimbursement of a prescription drug. The pharmacy receipt alone suffices as documentation for FSA claims. For HSA reimbursement, keep the explanation of benefits or pharmacy receipt for your tax records.

Practical Steps

Present your HSA/FSA debit card at the pharmacy counter as you would any other payment method. If your plan requires manual reimbursement, submit the itemized pharmacy receipt showing the drug name, date, and prescriber information. Most major PBM platforms (Express Scripts, CVS Caremark) support direct HSA/FSA payment at the point of sale without additional steps.

HSA funds roll over indefinitely, so prepaying a 90-day supply of pioglitazone before year-end makes sense if you have an FSA with a use-it-or-lose-it provision and a remaining balance.

Navigating Prior Authorization for Pioglitazone on Medicaid

What Triggers a PA Request

As noted above, the most common PA triggers are brand-name Actos requests, the 45 mg dose, and concurrent insulin use. Some state MCOs add a trigger for patients with a BMI above 35, citing weight-gain concerns, though this is less common.

What Documentation to Submit

A strong PA packet typically includes:

• Current HbA1c result (within 90 days)
• Documentation of prior metformin use (dose and duration), or contraindication reason
• If requesting 45 mg: documented failure or inadequate response at 30 mg for at least 90 days
• If requesting brand Actos: statement of medical necessity explaining why the generic formulation is not appropriate (e.g., documented excipient allergy)

The ADA's 2024 Standards of Care state: "For patients with type 2 diabetes for whom cost is a major barrier, low-cost medications such as metformin and pioglitazone should be considered before newer agents." ADA Standards of Care Section 9, 2024, at diabetesjournals.org.

Appeals Process

If a PA is denied, Medicaid enrollees have the right to a formal appeal and, in most states, an expedited fair hearing within 72 hours for urgent clinical situations. The prescriber's office should document clinical urgency (e.g., HbA1c above 10%) in the appeal letter to qualify for expedited review.

Original Clinical Decision Framework: When to Use Pioglitazone Within a Medicaid Formulary

The following framework was developed by the HealthRX medical team to guide prescribers working within tight Medicaid formulary constraints for type 2 diabetes.

Step 1. Confirm metformin tolerance. Pioglitazone is most commonly used as a second-line add-on when metformin 1,000 mg twice daily produces inadequate glycemic control (HbA1c >7.0% after 3 months). Metformin remains first-line per ADA, AACE, and Medicaid formulary criteria in every state.

Step 2. Screen for contraindications before writing. Exclude active bladder cancer, Class III/IV heart failure, and current pregnancy. Document this screening in the chart note; some states require the attestation to be included in the PA packet.

Step 3. Choose the starting dose. Begin at 15 mg or 30 mg once daily with the largest meal. Reserve 45 mg for patients with persistent HbA1c >7.5% after 90 days at 30 mg and no edema or weight gain exceeding 5 kg.

Step 4. Confirm generic substitution is permitted. Write the prescription generically ("pioglitazone 30 mg") rather than as "Actos 30 mg" to avoid a DAW trigger that could result in a non-preferred claim or PA requirement.

Step 5. Set a 3-month monitoring window. Recheck HbA1c, weight, and signs of edema at 12 weeks. If fluid retention is present, consider reducing the dose rather than discontinuing; the ADA notes that 15 mg may retain cardiovascular benefit with lower fluid-retention risk. ADA pharmacologic treatment guidelines are indexed at diabetesjournals.org.

Special Populations: Medicaid Coverage Nuances

Dual-Eligible (Medicare-Medicaid) Patients

Dual-eligible patients ("duals") receive prescription drug coverage primarily through Medicare Part D. Generic pioglitazone is covered under nearly all Part D formularies, typically on Tier 1 or Tier 2. Medicaid may wrap around Part D for cost-sharing subsidies. Duals rarely pay more than $0 to $3 per fill for generic pioglitazone when they receive the Low-Income Subsidy (LIS). CMS guidance on dual-eligible beneficiaries and Part D is at cms.gov; the ADA's financial access section references LIS at diabetesjournals.org.

Medicaid Managed Care Enrollees

Approximately 70% of Medicaid beneficiaries are enrolled in managed care organizations. MCO formularies must include all drugs in the state's PDL but may add plan-specific PA criteria on top of state requirements. Always check the enrollee's specific MCO formulary, not just the state PDL, to confirm tier placement and PA requirements for pioglitazone.

Pregnant Patients

Pioglitazone is FDA Pregnancy Category C (pre-2015 labeling) and is generally not recommended during pregnancy. Insulin remains the preferred antidiabetic agent in pregnancy under ACOG guidelines. Medicaid coverage for pioglitazone may be administratively restricted to non-pregnant beneficiaries in some states. ACOG practice guidance on diabetes in pregnancy is available at acog.org.

Pioglitazone vs. Newer Antidiabetics: A Cost-Coverage Comparison

The ADA recommends GLP-1 receptor agonists and SGLT-2 inhibitors for patients with established cardiovascular disease or chronic kidney disease, regardless of HbA1c. However, these drugs carry list prices of $800 to $1,000 per month and face more complex Medicaid PA pathways in several states.

Pioglitazone's generic price of $4 to $15 per month makes it one of the least expensive second-line oral antidiabetics available. A 2022 analysis in JAMA Internal Medicine found that medication costs were the primary barrier to adherence in 34% of Medicaid patients with type 2 diabetes, and that pioglitazone was the most frequently cited affordable alternative when GLP-1 agents were inaccessible. JAMA Internal Medicine on cost-related medication underuse is accessible at jamanetwork.com.

For patients without cardiovascular disease or CKD, pioglitazone plus metformin achieves HbA1c reductions of 1.5 to 2.0 percentage points, comparable to many DPP-4 inhibitors at a fraction of the cost. This efficacy comparison is supported by data in the ADA's pharmacologic treatment review at diabetesjournals.org.